Johanna Rimpilainen

Tampere, FI 
Clinical Trials:Currently Recruiting for 1 Trial
Tampere, FI 

Overview

Johanna Rimpilainen practices practicing medicine in Tampere, Finland.

Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Non-Hodgkin Lymphoma, and Mantle Cell Lymphoma (MCL).

She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Tampere, Finland
Other Locations
Oulu, Finland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
View 1 Less Clinical Trial

11 Total Publications

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.
Journal: British journal of haematology
Published: March 05, 2026

Frequently Asked Questions about Johanna Rimpilainen

Is Johanna Rimpilainen a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Johanna Rimpilainen is classified as an Experienced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Johanna Rimpilainen participate in research or clinical trials?

Yes. Johanna Rimpilainen has published 11 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Johanna Rimpilainen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rimpilainen's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile